Asia Deal Watch: CJ Group Continues Spree With Majority Stake Acquisition In Batavia Biosciences
Executive Summary
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
You may also be interested in...
Korean Firms Hunt For Overseas Biologics Manufacturers To Support Growth
Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.
Lynk Pursues Own R&D Path But Partnerships Still Key
As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.
Amneal Acquires India’s Puniska To Double Injectables Business
Amneal has acquired India’s Puniska Pharmaceticals in a deal worth $93m, with an aim to “more than double” its injectables business by 2025. Meanwhile, in the third quarter the company has reported growth in its generics and specialty segments, with Amneal looking to enter the biosimilars market next year.